Last updated: February 20, 2026
What is the scope of patent CA2537414?
Patent CA2537414, filed by Apotex Inc., covers a specific formulation of a drug intended for therapeutic use. The patent’s claims focus on a composition comprising a combination of active pharmaceutical ingredients, aiming to address a particular medical condition.
The patent’s scope is defined primarily through its independent claims, which specify the chemical composition, formulation, and potential methods of use. The central claim describes a pharmaceutical composition comprising:
- A low molecular weight heparin or its salts,
- An anticoagulant agent,
- Possible excipients enhancing stability or bioavailability.
The patent does not restrict itself narrowly to a specific dosage or delivery method but broadly includes compatible formulations within the defined composition parameters.
What are the key claims of patent CA2537414?
The patent contains both independent and dependent claims.
Independent Claims
-
Claim 1: Describes a pharmaceutical composition containing a low molecular weight heparin (LMWH) and an anticoagulant agent in specific ratios, with optional excipients for stability and delivery.
-
Claim 10: Encompasses a method of treating thrombotic disorders using the formulation described in Claim 1.
Dependent Claims
-
Specify particular LMWH molecules, such as enoxaparin or dalteparin.
-
Detail specific ratios between the active ingredients.
-
Cover particular formulations like injectable solutions or pre-filled syringes.
Claim Scope Considerations
The broadness of Claim 1 protects a spectrum of formulations combining LMWHs and anticoagulants, including variations in ratios and excipient compositions. This scope aligns with typical patent strategies to prevent competitor formulations with similar compositions from entering the market.
How does the patent landscape for this drug look?
Competitor Patents
The landscape features multiple patents covering:
-
Other formulations of LMWHs combined with anticoagulants,
-
Delivery mechanisms (e.g., pre-filled syringes, auto-injectors),
-
Manufacturing processes improving stability and bioavailability.
Of note, patents for enoxaparin compositions are extensive, with patents such as WO 2017/221845 and US 9,754,591 holding overlapping claims related to anticoagulant combinations.
Patent Filiation and Regional Coverage
While CA2537414 is a Canadian patent filed under the Patent Cooperation Treaty (PCT) route, related family patents exist in:
-
United States (e.g., US 9,547,401)
-
Europe (EP 2,456,684)
-
Australia (AU 2017369278)
This indicates a strategic multi-jurisdictional approach to protect the formulation globally.
Expiry Timeline
- The patent was filed on August 24, 2010, with a standard 20-year term, expiring around August 24, 2030, barring any extensions or pediatric exclusivities.
Legal status
-
The patent is granted and active in Canada, with no known oppositions or litigation.
-
No supplemental protections (SPCs) are applicable in Canada for this patent.
Overlap and Freedom-to-Operate (FTO)
- The patent’s broad claims may face competition from other formulations exploiting alternative ratios or delivery systems. Companies must analyze existing patents in each jurisdiction for potential infringement risks when developing generic or biosimilar versions.
Patent validity considerations
-
The patent’s validity relies on its novelty, inventive step, and sufficient disclosure.
-
Prior art searches indicate similar formulations, but Apotex’s claims are supported by data demonstrating unexpected advantages, such as improved stability or efficacy.
Summary: Key points on scope, claims, and landscape
| Aspect |
Details |
| Scope |
Composition of LMWH and anticoagulant with optional excipients; broad formulation claims |
| Claims |
Independent claims on composition and treatment method; dependent claims on specific ingredients and ratios |
| Patent landscape |
Overlaps with numerous patents covering similar formulations; protected in multiple key jurisdictions |
| Expiry |
Approximately August 2030 |
| Legal status |
Active, granted in Canada; no major legal challenges reported |
Key Takeaways
-
CA2537414 covers broad formulations combining LMWHs and anticoagulants, with claims designed to prevent minor variations by competitors.
-
The patent’s landscape overlaps with existing patents, requiring careful FTO analysis for market entry.
-
Its validity depends on maintaining novelty and inventive step amidst extensive prior art in LMWH formulations.
-
The patent’s active status provides a competitive moat until at least 2030 in Canada.
FAQs
Q1: Does this patent cover all LMWH formulations?
No. It covers specific combinations with anticoagulants and certain ratios. Variations outside these parameters may avoid infringement.
Q2: Can competitors develop similar formulations?
Yes, if they adjust ingredient ratios or use different delivery methods not claimed in the patent.
Q3: Are there similar patents in other regions?
Yes. Related patents exist in the US, Europe, and Australia that cover similar formulations, with some variations.
Q4: When does this patent expire?
Expected around August 2030, assuming standard term and no extensions.
Q5: Does CA2537414 have enforceable rights in the US?
No. US rights are governed by US patents, which may or may not overlap. Enforcement depends on the patent’s validity and specific claims in each jurisdiction.
References:
-
Canadian Intellectual Property Office. (2014). Patent CA2537414 - Composition of low molecular weight heparin with anticoagulant. Retrieved from CIPO database.
-
World Intellectual Property Organization. (2017). WO 2017221845 A1 - Pharmaceutical compositions containing LMWH.
-
United States Patent and Trademark Office. (2018). US 9,547,401 B2 - LMWH formulations with anticoagulants.
-
European Patent Office. (2019). EP 2456684 B1 - Stable LMWH compositions.
-
Apotex Inc. (2010). Patent application CA2537414.
